title: [Prostate specific antigen doubling time in prostate cancer before treatment and in refractory status].
abstract: Prostate-specific antigen(PSA) increases exponentially in prostate cancer patients before treatment and in refractory status. PSA increases in 68-86% of prostate cancer patients before treatment, and that of the remaining 14-32% of the patients is stable. Those patients with a higher pre-treatment PSA level are more likely to have a shorter PSA-doubling time(PSA-DT). The relationship between pre-treatment stage, grade and PSA-DT is controversial. PSA-DT in biochemical failure patients predicts the risk of clinical recurrence. PSA-DT was correlated well with time to clinical recurrence after biochemical failure. Distant recurrence was associated with short PSA-DT. Higher clinical stage and lower differentiation before treatment correlated with shorter PSA-DT in recurrent cancer patients. PSA-DT is an important parameter for judging malignant potential of each cancer.
authors.affiliation: Department of Urology, Isesaki Municipal Hospital.
authors.forename: S
authors.initials: S
authors.lastname: Nakata
authors.forename: Y
authors.initials: Y
authors.lastname: Takezawa
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
authors.forename: H
authors.initials: H
authors.lastname: Kuribara
authors.forename: K
authors.initials: K
authors.lastname: Matumoto
authors.forename: N
authors.initials: N
authors.lastname: Kosaku
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
authors.forename: H
authors.initials: H
authors.lastname: Yamanaka
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis*
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen